Paper709555
In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK and 3 others. Cancer Treat Rep, 1978. Cited by 258 papers, by iCite.
Cite this record
ConductScience Library. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Papers, record 709555. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/709555
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Leukemia, Experimental | Major topic |
| Animals | |
| Antibiotics, Antineoplastic | |
| Antineoplastic Agents | |
| Cell Line | |
| DNA, Neoplasm | |
| Daunorubicin | |
| Drug Resistance | |
| Mice | |
| RNA, Neoplasm |
Source PubMed
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 258 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40848933 | Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future. | J Mol Biol | 2026 | https://conductscience.org/library/papers/40848933 | PubMed |
| 29983877 | Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. | Oncotarget | 2018 | https://conductscience.org/library/papers/29983877 | PubMed |
| 22791660 | A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. | Oncotarget | 2012 | https://conductscience.org/library/papers/22791660 | PubMed |
| 12003193 | Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12003193 | PubMed |
| 10206276 | In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10206276 | PubMed |
| 9764579 | Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9764579 | PubMed |
| 9740539 | Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. | Invest New Drugs | 1998 | https://conductscience.org/library/papers/9740539 | PubMed |
| 8913834 | Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. | Invest New Drugs | 1996 | https://conductscience.org/library/papers/8913834 | PubMed |
| 8422694 | Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8422694 | PubMed |
| 7841045 | Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitising agent. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7841045 | PubMed |
| 7513620 | V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/7513620 | PubMed |
| 7296754 | Experimental in vivo cross-resistance of vinca alkaloid drugs. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7296754 | PubMed |
| 7105379 | Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105379 | PubMed |
| 6943568 | Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. | Proc Natl Acad Sci U S A | 1981 | https://conductscience.org/library/papers/6943568 | PubMed |
| 6938517 | Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro. | J Cancer Res Clin Oncol | 1980 | https://conductscience.org/library/papers/6938517 | PubMed |
| 6498081 | Cross-resistance to cytotoxic drugs in human glioma cell lines in culture. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6498081 | PubMed |
| 6149230 | Cells resistant to cytotoxic drugs are recognized by monoclonal antibody. | J Clin Immunol | 1984 | https://conductscience.org/library/papers/6149230 | PubMed |
| 4006047 | Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/4006047 | PubMed |
| 3886588 | The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3886588 | PubMed |
| 3858013 | Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3858013 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/709555
GET https://conductscience.org/api/papers/v1/709555/cited_by?page=2